Altasciences

Executive Summary

Altasciences is a mid-size contract research organization (CRO) that provides integrated early-phase drug development services, spanning preclinical safety testing, bioanalysis, clinical pharmacology (Phase I-II), and manufacturing. Operating across Canada and the United States, the company positions itself as a flexible partner for biopharmaceutical firms aiming to accelerate drug candidates from lead selection to proof of concept. Altasciences' end-to-end capabilities, combined with a proactive approach, enable sponsors to streamline development timelines and reduce risks. The company was founded in 2025 and is privately held, with recent enrichment data indicating ongoing operations in Laval, Quebec, and multiple U.S. sites. While Altasciences does not have publicly disclosed funding or valuation, its focus on early-phase services aligns with growing demand from biotech companies seeking efficient CRO partnerships to navigate the critical transition from preclinical to clinical development.

Upcoming Catalysts (preview)

• Q4 2026Announcement of strategic partnership or framework agreement with a top-20 biopharma company40% success
• Q1 2027Expansion of clinical pharmacology unit (CPU) capacity at a U.S. site55% success
• Q2 2027Regulatory clearance for a novel bioanalytical method supporting CNS or gene therapy programs30% success